{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:22:26Z","timestamp":1785558146473,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.clml.2021.07.014","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:33:07Z","timestamp":1626629587000},"page":"e975-e984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Florendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Stefania","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hearn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi","family":"Dhadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.014_bib0001","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2021.07.014_bib0002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/cancers13020215","article-title":"Treatment Strategies considering micro-environment and clonal evolution in multiple myeloma","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2021.07.014_bib0003","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.07.014_bib0004","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2018-99-115078","article-title":"Subsequent treatment outcomes of multiple myeloma refractory to CD38-monoclonal antibody therapy","volume":"132","author":"Cornell","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.014_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.014_bib0006","article-title":"Prescribing information","year":"2021","journal-title":"Reference ID"},{"key":"10.1016\/j.clml.2021.07.014_bib0007","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2021.07.014_bib0008","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-3-319-40320-5_9","article-title":"Management of transplant-eligible patients with newly diagnosed multiple myeloma","volume":"169","author":"Laubach","year":"2016","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clml.2021.07.014_bib0009","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/cam4.2698","article-title":"Utilization of novel systemic therapies for multiple myeloma: a retrospective study of front-line regimens using the SEER-Medicare data","volume":"9","author":"Goto","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.07.014_bib0010","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/14656566.2019.1577822","article-title":"The pharmacologic management of multiple myeloma in older adults","volume":"20","author":"Dempsey","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2021.07.014_bib0011","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.014_bib0012","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase i study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.014_bib0013","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.07.014_bib0014","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.18.02123","article-title":"Models of Palliative Care Delivery for Patients With Cancer","volume":"38","author":"Hui","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.014_bib0015","first-page":"3467","article-title":"Supportive care in cancer-a MASCC perspective","volume":"28","author":"Olver","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2021.07.014_bib0016","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.014_bib0017","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.014_bib0018","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.014_bib0019","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clml.2021.07.014_bib0020","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23991","article-title":"Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy","volume":"90","author":"Biran","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.07.014_bib0021","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","article-title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.014_bib0022","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","article-title":"Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma","volume":"132","author":"Bahlis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.014_bib0023","first-page":"56","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"Gasparetto","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.07.014_bib0024","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-139858","article-title":"Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.014_bib0025","article-title":"NCCN Clinical Practice Guidelines in Oncology","year":"2021","journal-title":"Antiemesis"},{"key":"10.1016\/j.clml.2021.07.014_bib0026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","article-title":"Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe","volume":"74","author":"Majumdar","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clml.2021.07.014_bib0027","article-title":"(rolapitant). Prescribing information","year":"2021","journal-title":"Reference ID"},{"key":"10.1016\/j.clml.2021.07.014_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1525-8610(04)70052-3","article-title":"Incidence of venous thromboembolism in megestrol acetate users","volume":"5","author":"Thomas","year":"2004","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.clml.2021.07.014_bib0029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-137183","article-title":"Selinexor in combination with carfilzomib and dexamethasone, all once weekly (SKd), for patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Gasparetto","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.014_bib0030","first-page":"45","article-title":"Selinexor, lenalidomide and dexamethasone (srd) for patients with relapsed\/refractory and newly diagnosed multiple myeloma","volume":"2","author":"White","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100286X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100286X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:55Z","timestamp":1761871075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502100286X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S215226502100286X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}